PPARα–NF-κB heterodimer mediates obesity-induced diastolic dysfunction through autocrine production of IL-6
Journal of Clinical Investigation · 2026
DOI: 10.1172/jci196238 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2026. Verfasst von Shin-Ichi Oka und 19 weiteren Autor:innen. Beteiligte Einrichtung: Rutgers New Jersey Medical School Department of Cell Biology and Molecular Medicine, Rutgers Biomedical and Health Sciences, Newark, New Jersey, USA. Hauptthemen laut MEDLINE: Interleukin-6, PPAR alpha, Obesity, Autocrine Communication. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NHLBI Division of Intramural Research, American Heart Association.
Abstract (Originalsprache)
Obesity is accompanied by increases in free fatty acids (FFAs) in the systemic circulation, and patients with obesity often develop cardiac hypertrophy and diastolic dysfunction, termed obesity cardiomyopathy. Proinflammatory cytokines, including IL-6, have been implicated in the pathogenesis of the cardiac dysfunction associated with obesity cardiomyopathy. Elevation of FFAs induced by high-fat diet (HFD) consumption induced diastolic dysfunction in the heart as early as after 1 month. HFD consumption directly stimulated IL-6 production in cardiomyocytes before local inflammation developed and induced diastolic dysfunction even in the presence of macrophage depletion with clodronate in the heart. PPARα played an essential role in mediating Il6 transcription in response to HFD consumption by forming a heterodimer with p50/RelA and binding to the NF-κB element in cardiomyocytes. Local production of IL-6 in cardiomyocytes, in turn, mediated the development of diastolic cardiac dysfunction. HFD-induced diastolic dysfunction was attenuated by cardiac-specific deletion of either Ppar α or Il6 , as well as by interference with the PPARα–NF-κB heterodimer formation by a molecular decoy. These results suggest elevated FFA levels directly upregulate Il6 through the PPARα–NF-κB heterodimer in cardiomyocytes and highlight autocrine production of IL-6 as a key downstream mechanism in the initial development of diastolic dysfunction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Rutgers New Jersey Medical School Department of Cell Biology and Molecular Medicine, Rutgers Biomedical and Health Sciences, Newark, New Jersey, USA.
- Precision Medicine Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Förderung
- NHLBI NIH HHS
- NHLBI Division of Intramural Research
- American Heart Association
- Fondation Leducq
- New Jersey Health Foundation
Zitieren
APA
Oka, S. I., Sung, E. A., Zhai, P., Schesing, K. B., Bhat, S., Chin, A., Park, J., Chung, Y. J., Shirakabe, A., Yamamoto, T., Ikeda, Y., Mizushima, W., Ikeda, S., Tong, M., Byun, J., Nakamura, M., Kim, S. I., Francisco, J., Del Re, D. P., & Sadoshima, J. (2026). PPARα–NF-κB heterodimer mediates obesity-induced diastolic dysfunction through autocrine production of IL-6. Journal of Clinical Investigation. https://doi.org/10.1172/jci196238
Vancouver
Oka SI, Sung EA, Zhai P, Schesing KB, Bhat S, Chin A, et al. PPARα–NF-κB heterodimer mediates obesity-induced diastolic dysfunction through autocrine production of IL-6. Journal of Clinical Investigation. 2026. doi:10.1172/jci196238
BibTeX
@article{Oka2026,
author = {Oka, Shin-Ichi and Sung, Eun-Ah and Zhai, Peiyong and Schesing, Kevin B and Bhat, Santosh and Chin, Adave and Park, Jiyeon and Chung, Yeun-Jun and Shirakabe, Akihiro and Yamamoto, Takanobu and Ikeda, Yoshiyuki and Mizushima, Wataru and Ikeda, Shohei and Tong, Mingming and Byun, Jaemin and Nakamura, Michinari and Kim, Samuel I and Francisco, Jamie and Del Re, Dominic P and Sadoshima, Junichi},
title = {PPARα–NF-κB heterodimer mediates obesity-induced diastolic dysfunction through autocrine production of IL-6},
journal = {Journal of Clinical Investigation},
year = {2026},
doi = {10.1172/jci196238}
}
EUVIMED